Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases

References

• Satoh M, Chan EKL, Sobel ES, Kimpel DL, Yamasaki Y, Narain S, et al. Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Exp Rev Clin Immunol. 2007;3: 721–38.
   PubMedGoogle Scholar
• Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997;40:1601–11.
   PubMed Web of Science ®Google Scholar
• Andrade LE, Chan EK, Peebles CL, Tan EM. Two major auto-antigen-antibody systems of the mitotic spindle apparatus. Arthritis Rheum. 1996;39:1643–53.
   PubMed Web of Science ®Google Scholar
• Eystathioy T, Chan EK, Tenenbaum SA, Keene JD, Griffith K, Fritzler MJ. A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol Biol Cell. 2002;13:1338–51.
   PubMed Web of Science ®Google Scholar
• Jakymiw A, Lian S, Eystathioy T, Li S, Satoh M, Hamel JC, et al. Disruption of GW bodies impairs mammalian RNA interference. Nat Cell Biol. 2005;7:1267–74.
   PubMed Web of Science ®Google Scholar
• Jakymiw A, Pauley KM, Li S, Ikeda K, Lian S, Eystathioy T, et al. The role of GW/P-bodies in RNA processing and silencing. J Cell Sci. 2007;120:1317–23.
   PubMed Web of Science ®Google Scholar
• Jakymiw A, Ikeda K, Fritzler MJ, Reeves WH, Satoh M, Chan EK. Autoimmune targeting of key components of RNA inter-ference. Arthritis Res Ther. 2006;8:R87.
   Web of Science ®Google Scholar
• Satoh M, Landon JJ, Chou CH, McCauliffe DP, Treadwell EL, Ogasawara T, et al. Characterization of the Su antigen, a mac-romolecular complex of 100/102 and 200 kDa proteins recognized by autoantibodies in systemic rheumatic diseases. Clin Immunol Immunopathol. 1994;73:132–41.
   PubMedGoogle Scholar
• Nozawa K, Fritzler MJ, Chan EK. Unique and shared features of Golgi complex autoantigens. Autoimmun Rev. 2005;4:35–41.
   Google Scholar
• Yamasaki Y, Honkanen-Scott M, Hernandez L, Ikeda K, Barker T, Bubb MR, et al. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/Ill antibodies. Arthritis Rheum. 2006;54:3051–6.
   PubMedGoogle Scholar
• Buchanan RR, Riglar AG. The titre of anti-centromere antibod-ies: its relationship to Raynaud's phenomenon and vascular occlusion. Br J Rheumatol. 1989;28:221–6.
   PubMedGoogle Scholar
• Sharp GC, Irvin WS, May CM, Holman HR, McDuffie FC, Hess EV, et al. Association of autoantibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systemic lupus erythematosus and other rheumatic diseases. N Engl J Med. 1976;295:1149–54.
   PubMed Web of Science ®Google Scholar
• Hoffman RW, Maldonado ME. Immune pathogenesis of mixed connective tissue disease: a short analytical review. Clin Immu-nol. 2008;128:8–17.
   PubMedGoogle Scholar
• Bodolay E, Csiki Z, Szekanecz Z, Ben T, Kiss E, Zeher M, et al. Five-year follow-up of 665 Hungarian patients with undifferen-tiated connective tissue disease (UCTD). Clin Exp Rheumatol. 2003;21:313–20.
   PubMed Web of Science ®Google Scholar
• Mosca M, Tani C, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology. Best Pract Res Clin Rheumatol. 2007;21:1011–23.
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of sys-temic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.
   PubMed Web of Science ®Google Scholar
• Reeves WH, Satoh M, Richards HB. Origins of antinuclear antibodies. In: Lahita RG, editor. Systemic lupus erythematosus, 4th ed. San Diego: Academic Press, 2004:401–31.
   Google Scholar
• Reeves WH, Narain S, Satoh M. Autoantibodies in systemic lupus erythematosus. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions. A textbook of rheumatology, 15th ed. Philadelphia: Lippincott Williams and Wilkins, 2005:1497–521.
   Google Scholar
• Karassa FB, Afeltra A, Ambrozic A, Chang DM, De Keyser F, Doria A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus ery-thematosus: an international meta-analysis. Arthritis Rheum. 2006;54:312–24.
   PubMed Web of Science ®Google Scholar
• Okano Y, Steen VD, Medsger TAJ. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med. 1993;119:1005–13.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Kaburaki J, Mimori T, Tojo T, Homma M. Auto-antibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest. 1993;91: 1399–404.
   Google Scholar
• Satoh M, Ajmani AK, Ogasawara T, Langdon JJ, Hirakata M, Wang J, et al. Autoantibodies to RNA polymerase ll are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (II0) form by a subset of human sera. J Clin Invest. 1994;94:1981–9.
   Google Scholar
• Steen VD. The many faces of scleroderma. Rheum Dis Clin North Am. 2008;34:1–15.
   PubMed Web of Science ®Google Scholar
• Fritzler MJ, Kinsella TD. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med. 1980;69:520–6.
   PubMed Web of Science ®Google Scholar
• Gelber AC, Pillemer SR, Baum BJ, Wigley FM, Hummers LK, Morris S, et al. Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma. Ann Rheum Dis. 2006;65:1028–32.
   PubMed Web of Science ®Google Scholar
• Hayashi N, Koshiba M, Nishimura K, Sugiyama D, Nakamura T, Morinobu S, et al. Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period. Mod Rheumatol. 2008;18:153–60.
   PubMedGoogle Scholar
• Kuwana M, Kimura K, Hirakata M, Kawakami Y, Ikeda Y. Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann Rheum Dis. 2002;61:842–6.
   Google Scholar
• Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, Wright TM, Curran-Everett D, West SG, et al. Anti-Th/To-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheu-matol. 2006;33:1600–5.
   Google Scholar
• Okano Y. Antinuclear antibody in systemic sclerosis (sclero-derma). Rheum Dis Clin North Am. 1996;22:709–35.
   PubMed Web of Science ®Google Scholar
• Medsger TM. Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ, editor. Arthritis and allied conditions. A text-book of rheumatology, 14th edn. Philadelphia: Lippincott Williams and Wilkins, 2001:1590–624.
   Google Scholar
• Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35:35–42.
   PubMed Web of Science ®Google Scholar
• Hirakata M. Humoral aspects of polymyositis/dermatomyositis. Mod Rheumatol. 2000;10:199–206.
   PubMedGoogle Scholar
• Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol. 2007;19: 523–9.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M. The precipitating antibody to an acidic nuclear protein anti-gen, the Jo-1, in connective tissue diseases. Arthritis Rheum. 1983;26:604–11.
   PubMed Web of Science ®Google Scholar
• Hirakata M, Suwa A, Takada T, Sato S, Nagai S, Genth E, et al. Clinical and immunogenetic features of patients with autoanti-bodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum. 2007;56:1295–303.
   PubMed Web of Science ®Google Scholar
• Takada T, Hirakata M, Suwa A, Kaneko Y, Kuwana M, Ishihara T, et al. Clinical and histopathological features of myopathies in Japanese patients with anti-SRP autoantibodies. Mod Rheumatol. 2008; in press.
   Google Scholar
• Cavazzana I, Ceribelli A, Quinzanini M, Scarsi M, Airo P, Cattaneo R, et al. Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. Lupus. 2008;17: 727–32.
   PubMedGoogle Scholar
• Rubin RL. Enzyme-linked immunosorbent assay for anti-DNA and antihistone antibodies including anti-(H2A-H2B). In: Rose NR, de Macario EC, Fahey JL, Friedman H, Penn GM, editors. Manual of clinical laboratory immunology, 4th ed. Washington, DC: American Society for Microbiology, 1992;735–40.
   Google Scholar
• Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28:859-90, viii.
   Google Scholar
• Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associa-tions in systemic sclerosis. Arthritis Rheum. 2005;52:2425–32.
   Google Scholar
• Kuwana M, Kimura K, Kawakami Y. Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked immuno-sorbent assay. Arthritis Rheum. 2002;46:2742–7.
   Google Scholar
• Santiago M, Baron M, Hudson M, Burlingame RW, Fritzler MJ. Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol. 2007;34:1528–34.
   Google Scholar
• Parker JC, Burlingame RW, Webb TT, Bunn CC. Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA. Rheuma-tology (Oxf). 2008;47:976–9.
   PubMedGoogle Scholar
• Reeves WH, Satoh M, Lyons R, Nichols C, Narain S. 2006. Detection of autoantibodies against proteins and ribonucleopro-teins by double immunodiffusion, immunoprecipitation, and western blotting. In: Rose NR, Hamilton RG, Detrick B, Reeves WH, editors. Manual of molecular and clinical laboratory immunology, 7th ed. Washington, DC: American Society of Microbiology Press, 2006:1007–18.
   Google Scholar
• Yamasaki Y, Narain S, Yoshida H, Hernandez L, Barker T, Hahn PC, et al. Autoantibodies to RNA helicase A: a new serological marker of early lupus. Arthritis Rheum. 2007;56:596–604.
   PubMedGoogle Scholar
• Bonilla E, Francis L, Allam F, Ogrinc M, Neupane H, Phillips PE, et al. Immunofluorescence microscopy is superior to fluo-rescent beads for detection of antinuclear antibody reactivity in systemic lupus erythematosus patients. Clin Immunol. 2007;124: 18–21.
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526–33.
   PubMed Web of Science ®Google Scholar
• Reimer G, Rose KM, Scheer U, Tan EM. Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest. 1987;79:65–72.
   PubMed Web of Science ®Google Scholar
• Takasaki Y, Yamanaka K, Takasaki C, Matsushita M, Yamada H, Nawata M, et al. Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod Rheumatol. 2004;14:367–75.
   PubMedGoogle Scholar
• Kakumanu P, Yamagata H, Sobel ES, Reeves WH, Chan EKL, Satoh M. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies but also react with unmodified arginine-containing peptide. Arthritis Rheum. 2008;58:1576–81.
   PubMedGoogle Scholar
• Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alex-ander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American—European Consensus Group. Ann Rheum Dis. 2002;61:554–8.
   Google Scholar
• McCauliffe DP, Wang L, Satoh M, Reeves WH, Small D. A recombinant 52 kD Ro (SS-A) ELISA detects autoantibodies in Sjogren's syndrome sera that go undetected by conventional serologic assays. J Rheumatol. 1997;24: 860–6.
   Google Scholar
• Nozawa K, Ikeda K, Satoh M, Reeves WH, Stewart CA, Li YC, et al. Autoantibody to nuclear antigen NA14 is an independent marker primarily for Sjogren's syndrome. Front Biosci. 2009;14: 3733–9.
   PubMed Web of Science ®Google Scholar